Comprehensive review evaluates liraglutide and metformin in type 2 diabetes, highlighting efficacy and safety. It suggests cost-effectiveness compared to other second-line treatments.
Key Points
Liraglutide significantly improves glycemic control in type 2 diabetes while reducing risk of hypoglycemia.
Clinical trials show liraglutide offers cardioprotective effects, lowering major adverse cardiovascular events.